“…Indeed, the FFA1 agonist fasiglifam entered phase III clinical trials; although it was clearly able to regulate glycemia and to produce clinically relevant lowering of hemoglobin A1c levels in patients with type 2 diabetes Poitout, 2013, 2015;Kaku et al, 2015), it was withdrawn from further trials because of concerns of possible liver toxicity. Although FFA4 is expressed in the pancreas (Stone et al, 2014;Suckow et al, 2014), where it may play roles in the regulation of glucagon production (Suckow et al, 2014), it is also expressed in various enteroendocrine cells (Parker et al, 2009;Iwasaki et al, 2015;Liu et al, 2015), adipocytes (Oh et al, 2010(Oh et al, , 2014Liu et al, 2015) and macrophages (Oh et al, 2010(Oh et al, , 2014Im, 2015;Liu et al, 2015). Potential combinations of effects on the release of incretins and/or satiety-regulating hormones in the gut, differentiation of and uptake of glucose by adipocytes, and control of the release of inflammatory mediators by macrophages have suggested that FFA4 might also be a useful therapeutic target to modulate insulin resistance and glucose homeostasis Oh et al, 2014;Liu et al, 2015;Milligan et al, 2015).…”